Maxim Group set a $9.00 price objective on Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) in a report released on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on KERX. Zacks Investment Research raised Keryx Biopharmaceuticals from a hold rating to a buy rating and set a $8.75 target price for the company in a research report on Wednesday, July 12th. BidaskClub lowered Keryx Biopharmaceuticals from a strong-buy rating to a buy rating in a research report on Wednesday, July 19th. Morgan Stanley reaffirmed an equal weight rating and set a $7.00 target price (up from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Cowen and Company reaffirmed a market perform rating on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Finally, ValuEngine lowered Keryx Biopharmaceuticals from a hold rating to a sell rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $8.11.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 0.212% during midday trading on Thursday, hitting $7.105. The company had a trading volume of 371,761 shares. The stock’s 50-day moving average price is $7.12 and its 200-day moving average price is $6.10. The stock’s market capitalization is $843.72 million. Keryx Biopharmaceuticals has a one year low of $4.03 and a one year high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.60. The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The firm’s revenue for the quarter was up 62.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.42) earnings per share. Analysts predict that Keryx Biopharmaceuticals will post ($0.93) EPS for the current year.

WARNING: This report was originally reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.watchlistnews.com/keryx-biopharmaceuticals-inc-kerx-given-a-9-00-price-target-by-maxim-group-analysts/1463818.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. OZ Management LP acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at $109,000. Usca Ria LLC acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at $128,000. Jane Street Group LLC acquired a new position in Keryx Biopharmaceuticals during the first quarter valued at $141,000. Legal & General Group Plc raised its position in Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares during the period. Finally, Lincoln Capital Corp raised its position in Keryx Biopharmaceuticals by 13.1% in the first quarter. Lincoln Capital Corp now owns 30,300 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 3,500 shares during the period. 62.35% of the stock is owned by hedge funds and other institutional investors.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.